Details for Patent: 9,370,582
Which drugs does patent 9,370,582 protect, and when does it expire?
Patent 9,370,582 protects LEQVIO and is included in one NDA.
This patent has forty-three patent family members in six countries.
Summary for Patent: 9,370,582
| Title: | Carbohydrate conjugates as delivery agents for oligonucleotides |
| Abstract: | The present invention provides iRNA agents comprising at least one subunit of the formula (I): |
| Inventor(s): | Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash Nair, Martin Maier |
| Assignee: | Alnylam Pharmaceuticals Inc |
| Application Number: | US14/329,557 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,370,582
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Start Trial | ||
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Start Trial | ||
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF ADULTS WITH HYPERCHOLESTEROLEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,370,582
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008333811 | ⤷ Start Trial | |||
| Australia | 2008340354 | ⤷ Start Trial | |||
| Australia | 2008340355 | ⤷ Start Trial | |||
| Canada | 2708153 | ⤷ Start Trial | |||
| Canada | 2708171 | ⤷ Start Trial | |||
| Canada | 2708173 | ⤷ Start Trial | |||
| Canada | 2910760 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
